← Search & browse all drugs
RESPIRATORY SYSTEM › NASAL PREPARATIONS › DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE › Antiallergic agents, excl. corticosteroids
cromoglicic acid
R01AC01
Forms & Strengths
- Nasal spray 0.5% solution
- Inhalation solution 2 mg/2 mL
- Oral capsules 200 mg
- Eye drops 0.1%
Adult Dosing
- Nasal: 2 sprays/nostril 2–4 times daily
- Inhalation (neb): 20 mg 4 times daily
- Inhalation (MDI): 200 µg 4 times daily for prophylaxis
- Eye drops: 1–2 drops each eye 4 times daily
Pediatric Dosing
- Nasal: 1–2 sprays/nostril 2–4 times daily (≥6 yr)
- Inhalation (neb): 10–20 mg 4 times daily (≥2 yr)
- Oral capsules: 100 mg 2 times daily (6‑12 yr)
- Eye drops: 1 drop each eye 4 times daily (≥3 yr)
Indications
- Allergic rhinitis
- Prophylaxis of asthma (including exercise‑induced)
- Mastocytosis skin lesions
- Allergic conjunctivitis
Mechanism of Action
- Stabilizes mast cell membranes
- Inhibits release of histamine, leukotrienes, prostaglandins
- Reduces eosinophil recruitment and activation
Contraindications
- Known hypersensitivity to cromoglicic acid or any formulation component
- Use as rescue therapy for acute bronchospasm
Adverse Reactions
- Nasal irritation or burning
- Throat irritation, cough, wheeze (especially with inhalation)
- Headache
- Rare bronchospasm
- Transient ocular burning with eye drops
Drug Interactions
- Additive bronchodilator effect with β2‑agonists
- May enhance corticosteroid efficacy in asthma
- Concurrent anticholinergics may reduce nasal absorption
- No significant cytochrome P450 interactions
Curated Content: Needs Vetting Before Put to Clinical Use